InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,870.62
(
-1.32%
)
US TECH 100
19,931.20
(
0.34%
)
Dow Jones
43,444.99
(
0.00%
)
Brent Oil
71.36
(
0.92%
)
Bitcoin
90,667.06
(
0.89%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1063
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 94

Sunday, 04/08/2018 2:01:25 PM

Sunday, April 08, 2018 2:01:25 PM

Post# of 438
CNAT failed a Ph2B post liver transplant HCV fibrosis study during 3/18.

CNAT's future relies on the fact that it has 3 more shots on goal. Based on these 3 results, NVS will decide whether to conduct (a) Ph3 (as a single agent or in combination with its own compound)study(ies).

The next result will be NASH cirrhosis and will read out H2/18.

has a cash runway that will take it thru these 3 studies.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up